{
    "organizations": [],
    "uuid": "2478f3d52ba95ec66c029c70b3cc416e18279ca6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-santhera-says-obtains-worldwide-ex/brief-santhera-says-obtains-worldwide-exclusive-license-from-polyphor-idUSFWN1Q508R",
    "ord_in_thread": 0,
    "title": "BRIEF-Santhera Says Obtains Worldwide Exclusive License From Polyphor",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :\n* SANTHERA OBTAINS WORLDWIDE EXCLUSIVE LICENSE FROM POLYPHOR TO DEVELOP AND COMMERCIALIZE CLINICAL STAGE CANDIDATE FOR CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-15T14:13:00.000+02:00",
    "crawled": "2018-02-16T16:34:49.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "santhera",
        "pharmaceutical",
        "holding",
        "ag",
        "santhera",
        "obtains",
        "worldwide",
        "exclusive",
        "license",
        "polyphor",
        "develop",
        "commercialize",
        "clinical",
        "stage",
        "candidate",
        "cystic",
        "fibrosis",
        "pulmonary",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}